| Title |
Bcr-Abl tyrosine kinase inhibitors- current status
|
|---|---|
| Published in |
Infectious Agents and Cancer, June 2013
|
| DOI | 10.1186/1750-9378-8-23 |
| Pubmed ID | |
| Authors |
Anum Mughal, Hafiz Muhammad Aslam, Aga Muhammad Hammad Khan, Shafaq Saleem, Ribak Umah, Maria Saleem |
| Abstract |
Bcr-Abl plays a central role in the development of chromosome positive leukaemia. Chronic Myeloid leukaemia occurs due to increase proliferation and resistance to apoptosis by Bcr-Abl positive cells. Imatinib (STI571) is the first drug in the family of Bcr-Abl tyrosine kinase inhibitors while Nilotinib (AMN107) and Dasatinib (BMS-345825) are second generation drugs that are intended to have less resistance and intolerance than imatinib. Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. 1, 3, 4 thiadiazole derivatives has also displayed moderate inhibitory action on both Abl and Src kinase family. However there are varieties of Bcr-Abl inhibitors but Nilotinib is still the frontline tyrosine kinase inhibitors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 23% |
| Researcher | 8 | 17% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Master | 5 | 10% |
| Student > Doctoral Student | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 10 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 11 | 23% |
| Biochemistry, Genetics and Molecular Biology | 10 | 21% |
| Chemistry | 8 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Medicine and Dentistry | 4 | 8% |
| Other | 0 | 0% |
| Unknown | 10 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2013.
All research outputs
#17,668,821
of 22,715,151 outputs
Outputs from Infectious Agents and Cancer
#295
of 514 outputs
Outputs of similar age
#140,877
of 196,714 outputs
Outputs of similar age from Infectious Agents and Cancer
#11
of 13 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 514 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,714 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.